Targeted drug trial aims to halt advanced cancers by blocking a key genetic driver
NCT ID NCT06390852
Summary
This trial is testing how well the drug larotrectinib works for people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug is designed to block the abnormal protein made by this gene change, which may slow or stop cancer growth. The study is for adults with various advanced or hard-to-treat cancers, including solid tumors, lymphoma, and multiple myeloma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.